Somatostatin was first suggested for the treatment of acute pancreatitis more than 15 years ago but despite many studies, its role in the management ofthis condition remains unclear. The experimental and clinical studies are reviewed and the physiological actions of somatostatin, which may influence the course of acute pancreatitis are examined. It is concluded that although some reports suggest a trend towards improved survival and lessened complication rate with somatostatin treatment, insufficient evidence of benefit exists to support the use of somatostatin or its analogue in the treatment or prophylaxis against acute pancreatitis in routine clinical practice.
It is conventional wisdom that 'to rest the gland' is beneficial in the management of acute pancreatitis. 2 Although the validity of this assumption has not been established it has led to clinical trials with nasogastric suction,'3 '4 cimetidine,5 16 and glucagon71 in the treatment of acute pancreatitis, none of which has been shown to be effective.
Somatostatin causes a dose dependent reduction in exocrine pancreatic secretion, the effect on enzyme secretion being greater than the effect on secretion of bicarbonate and water.'9 Similar effects have been shown with the somatostatin analogue, octreotide.2"2' In health, the doses of somatostatin used in clinical trials would be expected to cause a 70% reduction in exocrine pancreatic secretion. 19 This may explain the successful use of somatostatin analogues in the treatment of pancreatic fistulas3 and pseudocysts. 5 The secretory state of the pancreas, however, in acute pancreatitis is unknown, as is the effect of somatostatin on the diseased gland. In experimental models at least, pancreatic secretion seems to remain at basal values22 and there is evidence that pancreatic exocrine secretion is impaired in most patients after recovery from necrotising pancreatitis.23 HAEMODYNAMIC 
EFFECTS
Somatostatin reduces pancreatic blood flow in experimental animals. 24 The development ofpancreatic necrosis has been linked to hypoperfusion of the gland25 and vasoconstrictors have been shown to worsen the histological severity of experimental pancreatitis. 26 Conversely, dopamine, which improves pancreatic blood flow, has been found to improve the outcome from experimental pancreatitis. 27 Schroder et al found that, after the induction of pancreatitis, pancreatic blood flow decreased to a greater extent in somatostatin treated piglets than in untreated controls.28 This would be expected to be associated with a deleterious effect on outcome although no difference between treated and untreated animals was seen in this study. CYTOPROTECTION (Table I ). In the first study to be reported,37 Lankisch et al gave somatostatin at a dose of 100 ug/100 g body weight for three hours immediately after inducing pancreatitis in rats by the retrograde injection of sodium taurocholate into the pancreatic duct. Although the serum amylase and lipase were lower in the treatment group, the overall mortality was unchanged. The histological changes in the pancreas were also similar in the two groups. Two years later, Schwedes et al38 reported a significant histological benefit with cyclic somatostatin, 62 5 ug/h in a canine model of haemorrhagic pancreatitis. This effect was seen with both somatostatin pretreatment and with somatostatin given two hours after the induction of pancreatitis. The general condition ofthe animals in the treated group was also noted to be improved.
In addition to the different species used in these experiments, there are differences in experimental design which may help to explain these contradictory results. In inducing acute pancreatitis, Lankisch (Table II) .
In the one study to assess survival,43 a dramatic advantage was seen after twice daily subcutaneous octreotide at a dose of 2 ,ug/kg starting 12 hours after the induction of pancreatitis by pancreatic duct ligation. This survival advantage was similar to that reported by the same authors using native somatostatin. Augelli et al45 were able to show a reduction in histological severity in animals given octreotide, 5 ,ug/h, before the induction of pancreatitis although no effect was seen if treatment was delayed until pancreatitis was established despite continuing treatment for (Table III) . The incidence of acute pancreatitis in these studies is low and most studies do not have the statistical power necessary to exclude a therapeutic effect. One exception to this is the study by Guelrud et aP63 who studied a particularly high risk group of patients having pancreatic duct sphincter dilatation and found an overall incidence ofacute pancreatitis of 43%. Infusion of somatostatin for 12 hours perioperatively resulted in an incidence of acute pancreatitis of 25% compared with 75% in the placebo group. Another study, however, has reported a significant increase in the incidence of acute pancreatitis from 11% to 34% after the prophylactic use of octreotide,67 suggesting that the use of octreotide may even be harmful.
In conclusion, it is the authors' opinion that the evidence currently available does not support the use of somatostatin or its analogue for the treatment or prophylaxis against acute pancreatitis in routine clinical practice. 
